There’s no twisting of facts! The primary endpoint demonstrated clinical significance and NEWS2 secondary endpoint demonstrated statistical significance. Both of these markers would warrant a phase 3 trial on their own merits. The FDA authorized SOC shamdesivir didn’t meet its original primary endpoint in a phase 3 trial so they changed it to “trend towards” a positive result... So, are you trying to say it does or, that it doesn’t matter? I would venture to guess any doctor you come across would indicate a statistically significant NEWS2 result in any trial would be of interest!